KDR and neoplasm: Apatinib (Figure 3), an oral highly potent tyrosine-kinase inhibitor targeting VEGFR2 was observed to show the synergistic effect on anti-tumor activities of cisplatin on MDA-MB-231 TNBC cells by downregulating the levels of VEGFR2, AKT, and mTOR [60].